Skip to main content
Premium Trial:

Request an Annual Quote

BC Platforms: Mikaela Bruhammar

BC Platforms has hired Mikaela Bruhammar as its first chief operating officer for markets, with the primary responsibility for expanding the company's presence in the US. Bruhammar, who will be based in Switzerland, had served on the company's board of directors since 2021. She joins BC Platforms as a full-time employee from IQvia, where she most recently served as VP for real-world networks and partnerships in the Europe, Middle East, and Africa regions. Earlier, Bruhammar headed the respiratory, inflammation, and autoimmune disease business unit for AstraZeneca. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.